

# Hiroshige Yoshioka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1304313/publications.pdf>

Version: 2024-02-01

25  
papers

8,310  
citations

566801

15  
h-index

676716

22  
g-index

26  
all docs

26  
docs citations

26  
times ranked

8056  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 121-128.	5.1	3,794
2	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347
3	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2017, 390, 29-39.	6.3	753
4	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1&#x2013;2 study. <i>Lancet Oncology</i> , The, 2013, 14, 590-598.	5.1	555
5	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Na&#x201c;ve Patients With Advanced Non&#x201c;Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5240-5246.	0.8	161
6	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. <i>Lung Cancer</i> , 2016, 101, 1-8.	0.9	118
7	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2018, 23, 634-640.	1.0	103
8	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	0.9	100
9	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non&#x201c;small cell lung cancer harboring activating <i><sc>EGFR</sc></i> mutations: Subgroup analysis of <sc>LUX</sc>â&#x2013;Lung 3. <i>Cancer Science</i> , 2015, 106, 1202-1211.	1.7	99
10	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIa Non&#x201c;Small-Cell Lung Cancer With <i>EGFR</i> Mutation (IMPACT). <i>Journal of Clinical Oncology</i> , 2022, 40, 231-241.	0.8	61
11	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 32298-32304.	0.8	53
12	Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8117-8117.	0.8	36
13	Real&#x201c;world data on NGS using the Oncomine DxTT for detecting genetic alterations in non&#x201c;small&#x201c;cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	1.7	31
14	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. <i>Lung Cancer</i> , 2019, 129, 55-62.	0.9	29
15	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). <i>Lung Cancer</i> , 2019, 135, 175-180.	0.9	24
16	Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 267-269.	0.4	15
17	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non&#x201c;Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). <i>Clinical Lung Cancer</i> , 2022, 23, e257-e263.	1.1	10
18	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 6.	1.1	7

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302. <i>Oncology</i> , 2019, 97, 327-333.	0.9	5
20	Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. <i>Thoracic Cancer</i> , 2021, 12, 643-649.	0.8	5
21	Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer. <i>In Vivo</i> , 2018, 32, 1581-1586.	0.6	2
22	A randomized phase 3 study of maintenance therapy with Sâ€¹ plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sâ€¹ for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). <i>Cancer</i> , 2020, 126, 3648-3656.	2.0	2
23	A statistical issue regarding the original paper by M. Tamiya and others ( <i>Med Oncol</i> (2016) 33:2 DOI) Tj ETQq1 1 0.784314 rgBT /Overlo 1.2	0.784314	0
24	Consideration of the concordance rate of 22C3 and 28-8 antibody in NSCLC and its relation to the effect of nivolumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 143-143.	0.8	0
25	Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9114-TPS9114.	0.8	0